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RAS-signaling mutations induce the myelomonocytic differentiationand proliferation of hematopoietic stem and progenitor cells.Moreover, they are important players in the development of myeloid
neoplasias. RAF kinase inhibitor protein (RKIP) is a negative regulator of
RAS-signaling. As RKIP loss has recently been described in RAS-mutated
myelomonocytic acute myeloid leukemia, we now aimed to analyze its
role in myelomonocytic differentiation and RAS-driven leukemogenesis.
Therefore, we initially analyzed RKIP expression during human and
murine hematopoietic differentiation and observed that it is high in
hematopoietic stem and progenitor cells and lymphoid cells but decreases
in cells belonging to the myeloid lineage. By employing short hairpin RNA
knockdown experiments in CD34+ umbilical cord blood cells and the
undifferentiated acute myeloid leukemia cell line HL-60, we show that
RKIP loss is indeed functionally involved in myelomonocytic lineage com-
mitment and drives the myelomonocytic differentiation of hematopoietic
stem and progenitor cells. These results could be confirmed in vivo, where
Rkip deletion induced a myelomonocytic differentiation bias in mice by
amplifying the effects of granulocyte macrophage-colony-stimulating fac-
tor. We further show that RKIP is of relevance for RAS-driven myelomono-
cytic leukemogenesis by demonstrating that Rkip deletion aggravates the
development of a myeloproliferative disease in NrasG12D-mutated mice.
Mechanistically, we demonstrate that RKIP loss increases the activity of
the RAS-MAPK/ERK signaling module. Finally, we prove the clinical rele-
vance of these findings by showing that RKIP loss is a frequent event in
chronic myelomonocytic leukemia, and that it co-occurs with RAS-signal-
ing mutations. Taken together, these data establish RKIP as novel player in
RAS-driven myeloid leukemogenesis.
Introduction
Activating RAS-signaling mutations comprise sequence variants within the RAS
oncogenes themselves, but also can affect upstream activators and regulators of RAS-
signaling cascades. Among others, these include CBL, PTPN11, NF1 as well as a wide
range of receptor tyrosine kinases with relevance for physiological and malignant
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ABSTRACT
hematopoiesis. RAS-signaling mutations skew
hematopoiesis into the myelomonocytic lineage and ulti-
mately drive the proliferation of these cells.1
Mechanistically, they constitutively activate downstream
signaling cascades, including the RAS-mitogen activated
protein kinase/extracellular signal-regulated kinase
(MAPK/ERK) and Phosphoinositide 3-kinase/AKT path-
ways.2 While this already causes myelomonocytic lineage
commitment and increased proliferation of hematopoietic
stem and progenitor cells (HSPC) per se,1,3,4 it also increases
the sensitivity to granulocyte macrophage-colony-stimulat-
ing factor (GM-CSF),5 which augments these biological
effects even further. Importantly, both increased
myelomonocytic lineage commitment and proliferation are
considered as key steps in the pathogenesis of myelomono-
cytic leukemias. Indeed, RAS-signaling mutations are essen-
tial players within the development of these malignancies
and cause a myeloproliferative disease (MPD) with hyper-
proliferation of the monocytic and granulocytic lineages in
mice.6-9 In agreement with these data, RAS-signaling muta-
tions are frequently detected in myeloid neoplasias. More
than 10-20% of acute myeloid leukemia (AML) cases
exhibit either NRAS or KRAS mutations, respectively.10-12 A
myeloid neoplasia with particular dependence on aberrant
RAS-signaling is chronic myelomonocytic leukemia
(CMML), an aggressive malignancy characterized by
increased myelomonocytic differentiation and prolifera-
tion. Indeed, more than 40% of CMML patients exhibit one
or more mutations in the RAS-signaling genes.13,14 Recently,
it was shown that the extent of RAS-signaling activation in
myeloid neoplasias is not only determined by the presence
of mutations, but also by the aberrant expression profiles of
one or more of its regulators. This can also be of relevance
for RAS-driven myeloid leukemogenesis, as shown for the
RAS-signaling inhibitor SPRY2, which demonstrates
decreased expression levels in TET2-mutated patients.15
RAF kinase inhibitor protein (RKIP) is a negative regulator
of various intracellular signaling modules, including the
RAS-MAPK/ERK and nuclear factor-κB pathways.16,17 A
somatic loss of RKIP expression has been described in a
variety of solid cancers and a metastasis-suppressor func-
tion could be shown in vitro and in vivo.18,19 We have previ-
ously shown that a leukemia-specific loss of RKIP occurs in
patients with therapy-related AML with a predisposing
germline mutation in CRAF.20 On a functional level, RKIP
drives the oncogenic potential of mutant CRAF, thereby
contributing to leukemogenesis in these patients.
Subsequently, we could show that RKIP loss is of relevance
for other subtypes of AML as well.12,21,22 It occurs in up to
20% of AML cases and contributes to leukemogenesis by
increasing the proliferation of AML cells.12,21 In agreement
with the data from therapy-related AML 
(t-AML) patients with CRAF germline mutations, RKIP loss
is correlated with RAS-signaling mutations and increased
the leukemogenic potential of mutant RAS in a series of in
vitro assays. Interestingly, we observed that RKIP loss is also
correlated with myelomonocytic and monocytic AML phe-
notypes, which suggests that RKIP might play a role in
myelomonocytic differentiation as well.12,20,23
In this study, we aimed to clarify a connection between
RKIP and myeloid skewing of hematopoiesis in more
detail and demonstrate that RKIP loss contributes to
myelomonocytic lineage commitment of HSPC in vitro and
in vivo. We further show relevance of RKIP for 
RAS-driven myelomonocytic leukemogenesis, by demon-
strating that Rkip deletion aggravates myelomonocytic
MPD development in NrasG12D-mutated mice.
Mechanistically, we show that RKIP loss potentiates the
RAS-induced activation of the RAS-MAPK/ERK signaling
cascade. Finally, we prove the clinical relevance of these
findings by showing that RKIP loss is a frequent event in
primary CMML patient samples and frequently co-occurs
with RAS-signaling mutations. These data establish RKIP
as a novel player in RAS-driven myeloid leukemogenesis.
Methods
Primary patient samples and cell lines
Chronic myelomonocytic leukemia patient samples were col-
lected at the Division of Hematology, Medical University of Graz,
Austria, as well as in the Austrian Biodatabase for CMML. All
samples were processed and stored as described in detail in the
Online Supplementary Methods. Healthy CD34+ HSPC were collect-
ed from umbilical cord blood specimens (EasySep, STEMCELL
Technologies) according to the manufacturer´s instructions and
processed as described before.24 Peripheral blood samples from
healthy donors were used to collect CD14+ monocytes (MACS,
Miltenyi Biotec), B lymphocytes and granulocytes
(LymphoprepTM, STEMCELL Technologies and human 
B Lymphocyte enrichment set, BD biosciences) according to the
manufacturer’s protocol. 293T, NB4 and HL-60 cell lines were
obtained from the German National Resource Center for
Biological Material (DSMZ, Braunschweig, Germany). Low pas-
sage stocks were frozen and cells were always passaged for less
than six months after resuscitation. Additionally, cells were
screened by variable number of tandem repeat profiling (VNTR)
for authenticity.21 Lentiviral transduction of cell lines and primary
HSPC were performed as previously described.12,21,22
Mouse experiments
All mouse experiments were performed on a C57BL/6 strain
background. Survival analyses were based on groups of at least
eleven animals, all other experiments comprised at least three ani-
mals. Genotyping was performed using tail tips as previously
described.19,25 Mice with complete deletion of Rkip (Rkip-/-) as well
as their controls (Rkip+/+) were obtained from Professor John
Sedivy (Brown University, Providence, RI, USA). Mx1-Cre mice
were obtained from Dr. Karen Blyth (Cancer Research UK Beatson
Institute, Glasgow, UK), Nras-LSLG12D (JAX stock #008304; here-
after referred to as Nras) from The Jackson Laboratory (Bar
Harbor, ME, USA).26 Mx1-Cre and Nras animals were kept in a
heterozygous situation and crossed to Rkip-/- and Rkip+/+ mice to
obtain Mx1-Cre/Nras/Rkip-/- and Mx1-Cre/Nras/Rkip+/+ genotypes,
respectively. Detailed procedures of mouse analysis are presented
in the  Online Supplementary Methods.
Immunoblot analysis, real time quantitative 
polymerase chain reaction,  next-generation sequenc-
ing, flow cytometry and in vitro differentiation assays
These assays were extensively described previously11,21,22,27–30
and are presented in detail in the  Online Supplementary Methods. 
Database retrieval and statistical analyses
Microarray expression data for RKIP expression in murine
hematopoietic cell compartments were downloaded via the Gene
Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/), accession
numbers GSE27787,31 GSE5677,32 GSE2781633 and GSE20377.34
For the statistical analysis of in vitro and in vivo experiments, paired
and unpaired Student’s t-tests, respectively, were employed. For
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comparisons in primary patient samples, we used the Wilcoxon-
Mann-Whitney test for continuous variables and the Fisher’s Exact
test for dichotomous variables. The effects of RKIP expression on
survival were tested by the log-rank test. SPSS version 22.0 (SPSS
Inc.) was employed for these calculations. All tests were two-sided
and P<0.050 was considered statistically significant.
Study approval
The study was reviewed and approved by the institutional
review board (28-481 ex 15/16) and conducted in accordance with
the Declaration of Helsinki. Mouse experiments were approved
by the Federal Ministry for Science, Research and Economy (GZ:
BMWF-66.010/0050-II/3b/2013).
Results
RAF kinase inhibitor protein expression is high in
hematopoietic stem and progenitor cells and lymphoid
cells but low in cells belonging to the myeloid lineage 
Hypothesizing that RKIP loss is a driver for
myelomonocytic lineage commitment, one would assume
that cells with myelomonocytic differentiation would
demonstrate  lower RKIP expression levels. In a first step,
we therefore employed an HL-60 in vitro differentiation
model. HL-60 is an undifferentiated AML cell line and can
be forced into the myelomonocytic lineage by addition of
1,25 dihydroxyvitamin D3.35 Interestingly, we observed
that 1,25D3-induced differentiation in these cells was
accompanied by a significant decrease in the amount of
RKIP protein (P=0.002) (Figure 1A). We then aimed to
delineate RKIP expression in human hematopoiesis by
studying CD34+ HSPC derived from three umbilical cord
blood specimens on the one hand, as well as mature lym-
phocytes, granulocytes and monocytes from four healthy
individuals on the other. Due to the restricted cell num-
bers available, we studied RKIP mRNA by the means of
quantitative-polymerase chain reaction (qPCR) in these
experiments. However, we have previously shown that
decreased expression of RKIP at the protein level is accom-
panied by its downregulation at the mRNA level as
well.12,20-22 In accordance with HL-60 data, RKIP was
RKIP loss aggravates RAS-driven leukemogenesis
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Figure 1. RAF kinase inhibitor protein (RKIP) expression is low in cells belonging to the myeloid lineage. (A) Immature HL-60 acute myeloid leukemia (AML) cells
were treated with 100nM 1,25-dihydroxyvitamin D3 (1,25D3) for 48 hours to induce myeloid differentiation. Immunoblot analysis demonstrates a decrease in RKIP
protein expression in 1,25D3 treated cells. The graph represents the mean of three independent experiments ±Standard Deviation; expression values are given as 
x-fold expression of the HL-60 control. Statistical significance was evaluated using Student’s t-test. (B) Box plots showing RKIP mRNA expression, studied via quan-
titative polymerase chain reaction in CD34+ hematopoietic stem and progenitor cells (HSPC) (CD34+, n=3), lymphocytes (B-lymph, n=4), monocytes (Mono, n=4) and
granulocytes (Granulo, n=4) from healthy donors. In comparison to HSPC, RKIP mRNA expression is significantly reduced in monocytes and granulocytes, while no
significant difference was observed for lymphocytes. Graphs denote the x-fold RKIP expression levels of NB4 cells, which were used as a calibrator and arbitrarily set
to a value of 1. P-values were calculated using Student’s t-test. (C) Box plots showing that the expression of RKIP mRNA in differentiated cells belonging to the myeloid
lineage (MMC) is also decreased in mice. These data were generated by re-analysis of a previously published murine microarray gene expression profiling dataset.31
HSPC included long-term hematopoietic stem cells (lin–, Sca+, kit+, CD34–), short-term hematopoietic stem cells (lin–, Sca+, kit+, CD34+), LSK (lin–, Sca+, kit+) and
hematopoietic progenitor cells (lin–). Myelomonocytic cells (MMC) included Gr-1+ neutrophils and Mac-1+ monocytes/macrophages. Statistical significance was cal-
culated by Student’s t-test.
A
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prominently expressed in healthy CD34+ HSPC (Figure
1B). RKIP expression levels in lymphocytes were similar to
those observed in HSPC (P=0.244), while they were signif-
icantly reduced in monocytes (P=0.001) and granulocytes
(P<0.001). 
Finally, we sought to confirm these findings in a murine
setting. We therefore performed a database retrieval via
the Gene Expression Omnibus (GEO) database and re-
analyzed RKIP mRNA in a previous publication of
Konuma et al.31 (GEO data set GDS3997) who performed
microarray analyses in different hematopoietic cell and
progenitor compartments in C57BL/6 mice. In agreement
V. Caraffini et al.
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Figure 2. RAF kinase inhibitor protein (RKIP) is functionally involved in myeloid lineage differentiation. (A) RKIP shRNA knockdown (KD) in CD34+ human hematopoi-
etic stem and progenitor cells (HSPC) increased the myelomonocytic differentiation induced by a granulocyte-macrophage colony-stimulating factor (GM-CSF)/flt-3
ligand (FL)/stem cell factor (SCF)/tumor necrosis factor-α (TNFα) cytokine mix. (Left) Immunoblot  showing the successful knockdown of RKIP. Control KD denotes
control transduced cells. Representative flow cytometry plots showing increased expression of the myelomonocytic surface markers CD11b and CD14 in CD34+
HSPC with RKIP KD shown in the middle. (Right) Results of all six experiments performed; median is also shown. Statistical significance was calculated by Student´s
t-test. Of note, RKIP KD as a single event without the addition of cytokines was insufficient to induce differentiation (data not shown). (B) RKIP KD in HL-60 AML
cells increased 1,25D3-induced myelomonocytic differentiation, as assessed by flow cytometric expression of CD11c. (Left) Immunoblot  showing the successful
knockdown of RKIP; (right) mean CD11c expression of three independent experiments ±Standard Deviation (SD); expression values are given as x-fold expression
of HL-60 control KD cells, statistical significance was evaluated by Student’s t-test. (C) RKIP overexpression (RKIP OE) in HL-60 AML cells reduced 1,25D3 induced
myelomonocytic differentiation, as assessed by flow cytometric expression of CD11c. HL-60 cells were transduced with eGFP-C1-6xG-hRKIP (RKIP OE) or empty vec-
tor (control OE). (Left) Immunoblot showing successful RKIP overexpression; (right)  mean CD11c expression of three independent experiments ±SD. Expression val-
ues are given as x-fold expression of HL-60 control OE cells. Statistical significance was evaluated by Student’s t-test. Note that HL-60 cells were treated with 10nM
1,25D3.
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with our findings in HL-60 and in healthy human individ-
uals, RKIP mRNA levels were high in HSPC and lympho-
cytes but significantly reduced in more differentiated cells
of the myeloid lineage (P<0.001) (Figure 1C). Of note, by
focusing on specific HSPC compartments within
GDS3997 and three additional datasets,31-34 we observed
that RKIP expression remains high until the granulocyte-
macrophage-progenitor (GMP) stage and decreases during
the terminal stages of myelomonocytic differentiation
(Online Supplementary Figure S1).
Knockdown of RAF kinase inhibitor protein amplifies
the myelomonocytic differentiation of hematopoietic
stem and progenitor cells  
Having shown that RKIP levels are high in HSPC and
reduced in differentiated myeloid cells, we next aimed to
investigate whether RKIP expression levels are of func-
tional relevance for the myeloid lineage commitment of
HSPC. Therefore, we performed lentiviral knockdown of
RKIP in CD34+ human HSPC isolated from umbilical cord
blood specimens (Figure 2A). Subsequently, cells were
RKIP loss aggravates RAS-driven leukemogenesis
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Figure 3. Rkip deletion causes increased myeloid lineage commitment in a murine model by increasing the sensitivity to granulocyte-macrophage colony-stimu-
lating factor (GM-CSF). (A) To assess the effects of GM-CSF in vivo, four mice with a deletion of Rkip (Rkip-/-), as well as four control mice (Rkip+/+) were injected
intraperitoneally with 500ng GM-CSF twice a day for four days and were analyzed on day 5. (B) Cytological analysis of peripheral blood smears from these mice
revealed a significant increase in the number of myelomonocytic cells (MMC) in Rkip-/- animals. A representative peripheral blood smear picture is shown. Lymphoid
cells are shown as LYM. Graphs show the average ±Standard Deviation (SD). Statistical significance was evaluated by Student’s t-test. (C) Representative flow cyto-
metric plots of the mice presented in (B) showing an increased percentage of CD11b+ and CD11b+ Ly6G+ cells in the bone marrow (BM), peritoneal cavity (PC), and
peripheral blood (PB) of Rkip-/- mice. Graphs show the average ±SD. Statistical significance was evaluated by Student’s t-test. RKIP: RAF kinase inhibitor protein.
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C
treated with a granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF)/flt-3 ligand (FL)/stem cell factor
(SCF)/tumor necrosis factor-α (TNFα) cytokine mix to
induce myelomonocytic differentiation.29 Five days later,
the expression of myelomonocytic surface markers
CD11b and CD14 was assessed. In these experiments,
myelomonocytic differentiation was significantly
increased in HSPC transduced with the RKIP shRNA
V. Caraffini et al.
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Figure 4. Deletion of Rkip aggravates
myeloproliferation and myeloprolif-
erative disease (MPD) development
in Nras-mutated mice. An Nras driv-
en mouse model of myeloprolifera-
tion (Mx1-Cre/Nras) was used to
study the effects of Rkip-/- on Ras-dri-
ven myeloproliferation and MPD
development. Mice were electively
killed at an age of six months after
the first pIpC injection, 
Mx1-Cre/Nras/Rkip-/- mice (n=3)
were compared to control mice (Mx1-
Cre/Nras/Rkip+/+; n=3) as well as to
mice without Mx1-Cre (Nras/Rkip+/+;
n=4). (A) Representative images of
spleens from Nras/Rkip+/+, 
Mx1-Cre/Nras/Rkip+/+ and 
Mx1-Cre/Nras/Rkip-/- mice as well as
bar graphs of spleen lengths and
weights, showing splenomegaly in
animals with Rkip deletion. (B)
Representative flow cytometric plots
showing an increase in the percent-
age of CD11b+ and CD11b+ Ly6G+
myelomonocytic cells in peripheral
blood (PB), bone marrow (BM) and
spleen (SP) of Mx1-Cre/Nras/Rkip-/-
mice when these were compared to
Nras/Rkip+/+ animals as well as when
compared to Mx1-Cre/Nras/Rkip+/+
littermates. (C) Peripheral blood
counts demonstrate an increased
number of white blood cells (WBC) in
Mx1-Cre/Nras/Rkip-/- mice. (D) The
leukocytosis in Mx1-Cre/Nras/Rkip-/-
mice is caused by an increased num-
ber of myelomonocytic cells (MMC),
as shown in the representative PB
smear and as shown in the flow cyto-
metric analyses shown above.
Graphs show the average ± Standard
Deviation. Statistical significance
was calculated by Student’s t-test.
RKIP: RAF kinase inhibitor protein.
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(HSPC RKIP KD) as compared to HSPC control KD
(P=0.001 for CD11b+ cells and P=0.002 for CD11b+ CD14+
cells) (Figure 2A), confirming a role of RKIP loss in myeloid
differentiation of HSPC. RKIP KD as a single event with-
out the addition of cytokines was insufficient to induce
myelomonocytic differentiation (data not shown). Of note,
RKIP is a negative regulator of RAS-MAPK/ERK signaling.
To evaluate whether RKIP KD indeed enhances 
RAS-MAPK/ERK signaling in HSPC, we studied the phos-
phorylation of ERK (pERK) in the conditions mentioned
above. Indeed, HSPC with RKIP KD displayed increased
pERK levels (Figure 6A), suggesting that the RKIP-induced
aggravation of differentiation might be mediated via acti-
vation of the RAS-MAPK/ERK pathway. 
To further corroborate the role of RKIP in myelomono-
cytic differentiation, we again employed the 1,25D3-based
HL-60 differentiation model and performed additional
RKIP modulation by transfection of RKIP siRNA and over-
expression constructs, respectively (Online Supplementary
Figure S2). Initially, we thereby sought to confirm the role
of RKIP on RAS-MAPK/ERK signaling and therefore stud-
ied the expression of pERK. In agreement with the results
from healthy CD34+ HSPC, RKIP KD thereby increased
pERK levels, which corroborates the role of RKIP as a reg-
ulator of RAS-MAPK/ERK signaling (Figure 6B). To study
the role of RKIP on myelomonocytic differentiation, we
assessed the CD11c surface expression in these experi-
ments, which was previously established as the most suit-
able marker for this HL-60-based experimental approach.36
1,25D3-treated HL-60 cells harboring RKIP knockdown
thereby demonstrated an increased potential to differenti-
ate into the myeloid lineage as assessed by an increase in
the expression of CD11c (P=0.009) (Figure 2B). The oppo-
site effect was observed after RKIP overexpression
(P=0.005) (Figure 2C). Finally, we studied the effect of
RKIP modulation without additional 1,25D3 incubation.
As seen for healthy HSPC, myelomonocytic differentia-
tion could not be induced in this scenario (P=0.112 for
RKIP knockdown and P=0.168 for RKIP overexpression).
Rkip deletion contributes to the development of a
myelomonocytic-lineage-biased hematopoietic system
in a murine in vivo model 
After demonstrating the functional involvement of RKIP
loss in myelomonocytic differentiation in vitro, we focused
on its effects in vivo. To do this, we analyzed the
hematopoietic system in a murine model with a complete
deletion of Rkip (Rkip-/-) (Online Supplementary Table S1 and
Online Supplementary Figures S3 and S4). In agreement with
the in vitro data, RKIP loss as a single event thereby proved
insufficient to increase the amount of myelomonocytic
cells. Rkip deletion alone further proved insufficient to
increase the proliferation of specific HSPC compartments
(Online Supplementary Figure S4). As our in vitro data
already suggested that RKIP acts as a modulator for the
sensitivity to extracellular inducers of differentiation, we
aimed to challenge the hematopoietic system of Rkip-/-
mice by the additional intraperitoneal injection of GM-
CSF in a next step (Figure 3A). Indeed, Rkip-/-mice demon-
strated an increased percentage of CD11b+ as well as
CD11b+ Ly6G+ myelomonocytic cells in bone marrow,
peritoneal cavity cells and peripheral blood in these exper-
iments (Figure 3B and C). As seen in the in vitro experi-
ments mentioned above, Rkip deletion also enhanced
RAS-MAPK/ERK signaling, as evidenced by increased
pERK levels in Rkip-/-mice (Figure 6C). Taken together, our
RKIP loss aggravates RAS-driven leukemogenesis
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Figure 5. Induction of myeloproliferation in Nras-mutated mice with Rkip deletion coincides with a mitigation of histiocytic sarcoma development. Representative
Hematoxylin & Eosin stained sections of spleen and liver of the mouse genotypes as indicated. Mice were electively killed at an age of six months after the first pIpC
injection. As in the flow cytometric analyses, animals with Rkip deletion demonstrated increased myeloproliferation (spleen, bottom left and insert bottom left show-
ing multiple megakaryocytes) as compared to the Rkip+/+ mice (spleen top left, and insert top left showing almost exclusively histiocytic sarcoma). The formation of
histiocytic sarcomas was mitigated in the Rkip deleted genotypes as also clearly seen in the liver sample (bottom right, no infiltrate) compared to the Rkip+/+ liver
showing infiltration by histiocytic sarcoma (top right, arrow). The black bar denotes a distance of 500 mm. RKIP: RAF kinase inhibitor protein.
data indicate that RKIP loss enhances RAS-MAPK/ERK
signaling on the one hand and increases GM-CSF-induced
myelomonocytic lineage commitment and differentiation
of HSPC on the other. Furthermore, they suggest that
RKIP exerts its role in terminal myelomonocytic differen-
tiation by acting as a rheostat that modulates the sensitiv-
ity to external stimuli, such as 1,25D3 and growth factors,
respectively. 
Rkip deletion aggravates myeloproliferation and the
development of a myelomonocytic myeloproliferative
disease in Ras-mutated mice
Increased myelomonocytic lineage commitment is a key
step in myeloid leukemogenesis. However, Rkip-/- mice
failed to develop myeloid neoplasias in our study (data not
shown). As the functional assays delineating the role of
RKIP in myelomonocytic differentiation suggested that
RKIP rather acts as an amplifier of activated GM-CSF/RAS
signaling, we next crossed Rkip-/-mice with Mx1-Cre/Nras-
mutated animals (Online Supplementary Figure S5). The
Mx1-Cre/Nras was chosen because: (i) RKIP loss and 
RAS-signaling mutations have previously been shown to
co-occur in AML;12,20,22 and (ii) RKIP loss has been demon-
strated to potentiate the oncogenic effects of RAS-signal-
ing mutations in functional in vitro assays.12,20 Interestingly,
Mx1-Cre/Nrasmice on a pure C57BL/6 background devel-
op a myeloproliferation that preferentially affects the
myelomonocytic lineages. However, previously published
data have demonstrated that these mice ultimately suc-
cumb to histiocytic sarcomas (HS) and only randomly
develop a full blown MPD.8 In the current study, we elec-
tively analyzed mice at an age of six months after the first
pIpC injection and thereby observed that myeloprolifera-
tion was aggravated in Mx1-Cre/Nras/Rkip-/- mice, who
consistently demonstrated splenomegaly, as well as
increased myeloid infiltration of bone marrow, spleen and
liver as compared to Nras/Rkip+/+ and to Mx1-
Cre/Nras/Rkip+/+ animals (Figures 4A and B, and 5). In addi-
V. Caraffini et al.
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Figure 6. RAF kinase inhibitor protein (RKIP) regulates RAS-MAPK/ERK signaling in the myeloid system. (A) RKIP shRNA knockdown (KD) in CD34+ human
hematopoietic stem and progenitor cells (HSPC) increased RAS-MAPK/ERK signaling, as measured by the phosphorylation of ERK (pERK). (Left) A representative
immunoblot. Graph represents the mean of three independent experiments ±Standard Deviation (SD); pERK intensity is given as x-fold change to the CD34+ control
KD. (B) RKIP shRNA KD in HL-60 increased pERK levels as well. (Left) Representative immunoblot. Graph represents the mean of three independent experiments
±SD; pERK intensity is given as x-fold change to the HL-60 control KD. (C) Rkip deletion enhanced the activity of RAS-MAPK/ERK signaling in CD11b+ cells isolated
from the bone marrow of mice. (Left) A representative immunoblot. Graph represents the mean of three independent experiments ±SD; pERK intensity is given as
x-fold change to the Rkip+/+ control genotype. (D) Rkip deletion also increased the activity of RAS-MAPK/ERK signaling in CD11b+ cells isolated from Nras-mutated
mice. A representative immunoblot and the graph is presented as described above, Mx1-Cre/Nras/Rkip+/+ were used as control group. Mice experiments were per-
formed using n=3 mice for each genotype. Statistical significance was evaluated by Student’s t-test in all cases.
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tion, only the Mx1-Cre/Nras/Rkip-/- genotype exhibited a
full blown MPD, as evidenced by an accompanying leuko-
cytosis in the peripheral blood (Figure 4C and D, and
Online Supplementary Table S2).37 We then studied a poten-
tial involvement of the RAS-MAPK/ERK pathway in this
process. As seen in the experiments described above, Rkip
deletion again enhanced the activation of ERK.
Importantly, these effects on RAS-MAPK/ERK signaling
were visible both in the absence of mitogens and follow-
ing GM-CSF stimulation (Figure 6D and Online
Supplementary Figure S6). In agreement with data from Li et
al.,8 HS were detected in all Nras-mutated mice studied;
however, the phenotype was mitigated in the Mx1-
Cre/Nras/Rkip-/- animals. Transformation into secondary
AML did not occur in any of the mice, as assessed by mor-
phological and flow cytometric evaluation of peripheral
blood, bone marrow and spleen (data not shown).
Interestingly, although MPD development was aggravated
in Mx1-Cre/Nras/Rkip-/- animals, the median survival was
similar between Mx1-Cre/Nras/Rkip-/- and 
Mx1-Cre/Nras/Rkip+/+ mice (P=0.339) (Online
Supplementary Figure S7). Histopathological examination
of moribund Mx1-Cre/Nras/Rkip+/+ mice thereby revealed
that these mice suffered from extensive HS (Online
Supplementary Table S3 and Online Supplementary Figure
S8). In agreement with the data from 6-month old mice,
the Mx1-Cre/Nras/Rkip-/- mice had a mitigated HS pheno-
type but an increased myeloproliferation/MPD occur-
rence. Future studies, using models without the predispo-
sition to HS, will, therefore, be necessary to unambigu-
ously delineate the effect of Rkip on the survival of 
Ras-driven MPD.
Taken together, these data indicate that RKIP aggravates
the effects of mutated Nras on RAS-MAPK/ERK signaling
on the one hand, as well as on myeloproliferation and
MPD development on the other. 
RAF kinase inhibitor protein loss is frequently
observed in primary chronic myelomonocytic leukemia
patient specimens and co-occurs with RAS-signaling
mutations
Finally, we aimed to delineate the clinical relevance of
these findings and therefore analyzed a cohort of 41 pri-
mary CMML patients' specimens for RKIP protein expres-
sion by immunoblot (Figure 7A and B; for details of clini-
cal characteristics as well as treatment regimens adminis-
tered see Online Supplementary Table S4). We chose this
disease because increased myelomonocytic lineage com-
mitment and pathological RAS-signaling are seminal steps
in its pathogenesis. RKIP protein loss was defined as pre-
viously reported12,22 and could be detected in 12 of 41
(29.3%) of CMML patients' samples. Interestingly, RKIP
loss at the protein level also correlated with decreased
expression of its mRNA (P<0.001) (Figure 7C). This is in
agreement with data from AML, where RKIP loss has
been shown to be caused by increased expression of miR-
23a,21,22 and suggests that a similar mechanism might be
present in CMML as well. Most interestingly, however,
we observed that RKIP loss correlated with a more pro-
nounced myelomonocytic phenotype, as assessed by the
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Figure 7. Loss of RAF kinase inhibitor protein
(RKIP)  is a frequent event in primary chronic
myelomonocytic leukemia (CMML) patients'
samples. (A) Loss of RKIP at protein level was
observed in 12 of 41 (29.3%) of cases. A rep-
resentative immunoblot is shown, with RKIP
protein loss being present in patients 8039,
7156 and 7954. (B) Graphs showing the x-fold
change in RKIP protein expression as com-
pared with NB4 acute myeloid leukemia (AML)
cells, which were chosen as a calibrator due to
their physiological RKIP expression levels.12
The expression of NB4 was arbitrarily set to 1.
(C) Box plots illustrating RKIP mRNA levels in
CMML patients with and without RKIP loss at
the protein level. NB4 AML cells served as cal-
ibrator and statistical significance was calcu-
lated by the Wilcoxon-Mann-Whitney test.
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percentage of myelomonocytic cells (MMC; monocytes
and granulocytes) in the peripheral blood (86% vs. 76%,
P=0.030) (Online Supplementary Table S4). This is in agree-
ment with our functional data and with previous findings
from AML.12 To investigate the molecular landscape of
CMML patients with RKIP loss, we performed next-gen-
eration sequencing (NGS) covering 39 genes with recur-
rent mutations in myeloid neoplasms (Figure 8). In total,
these analyses could be performed in 37 of 41 patients.
All together, we discovered 186 mutations in 37 of 37
(100%) of the patients. Thirty-three of 37 had more than
one mutation with a median of four variants per sample
(range 1-32). In agreement with previous studies,38 the
most frequently affected genes were TET2 (75.7%),
SRSF2 (46.0%), CBL (24.3%), and ASXL1 (24.3%).
Mutations in NRAS and KRAS affected 13 of 37 (35.1%)
of the patients (Online Supplementary Table S5). This high
frequency was even increased, when mutations affecting
RAS-signaling were grouped (including NRAS, KRAS,
CBL, PTPN11, FLT3, CSF3R, KIT, JAK2, and NF1).
Twenty-nine of 37 (78.4%) of CMML patients' specimens
showed one or more mutations within these genes. Most
interestingly, however, almost all patients with RKIP loss
(11 of 12, 91.7%) exhibited one or more mutations in
RAS-signaling genes. Together with the previously pub-
lished data from AML, this indicates that RKIP loss and
RAS-signaling mutations co-occur in myeloid neoplasms,
which proves the clinical relevance of the functional in
vivo data mentioned above. Of note, RAS-signaling muta-
tions were also frequent in patients with normal RKIP
expression (18 of 25, 72%; comparison to patients with
RKIP loss, P=0.232), which suggests that RKIP loss is not
the only second genetic hit that interacts with RAS-signal-
ing mutations in myeloid leukemogenesis. Indeed, such
interactions have previously been shown for a variety of
genetic aberrations, including aberrant expression of
members of the dual specificity phosphatase (DUSP) and
SPROUTY (Spry) families, as well as for mutations in
ASXL1 and TET2.15,39-41 Finally, overall survival (OS) was
similar between patients with and without RKIP loss
(P=0.913) (Online Supplementary Figure S9). It must be
noted, however, that these analyses are limited by the
fact that these patients were managed with different
treatment modalities, which ranged from best supportive
care to high-dose chemotherapy. Subgroup analyses
focusing on uniformly treated patients only could not be
carried out due to the small sample size of this cohort. 
Discussion
Hematopoietic stem and progenitor cells have the
potential to differentiate into both myeloid and lymphoid
hematopoietic cells. Although tight control and regula-
tion programs are in place to maintain this system in
homeostasis, skewing of hematopoiesis into the myeloid
lineage can be achieved by a multitude of genetic aberra-
tions. This includes RAS-signaling mutations,1 which
drive the myelomonocytic lineage commitment by
increasing the sensitivity of intracellular signaling cas-
cades to extracellular growth factors, such as GM-CSF.5,42
In this study, we hypothesized that a loss of the RAS-sig-
naling inhibitor RKIP plays a role in myelomonocytic dif-
ferentiation as well. Therefore, we initially analyzed
RKIP expression during human and murine hematopoiet-
ic differentiation and observed that it is high in HSPC and
lymphoid cells but decreases in cells belonging to the
myeloid lineage. By modulating RKIP expression in
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Figure 8. RAS-signaling mutations are frequent in chronic myelomonocytic leukemia (CMML) patients with RAF kinase inhibitor protein (RKIP) loss. Thirty-nine
genes with recurrent mutations in myeloid neoplasias were screened for mutations by the means of next-generation sequencing.11 The heatmap shows the distribu-
tion and number of mutations observed in each CMML patient (n=37). Every column describes one CMML patient specimen, defined as either “RKIP loss” or “RKIP
normal” according to the immunoblot results. Light purple indicates the presence of one mutation; dark purple is used to demonstrate the presence of multiple
mutations. Genes without sequence variations in any of the patients are not shown.
healthy HSPC and undifferentiated AML cell lines, we
could further show that loss of RKIP expression is an
important driver of myelomonocytic lineage commit-
ment. This could be corroborated in subsequent in vivo
studies, where we did show that RKIP loss increases the
activation of RAS-MAPK/ERK signaling, and consequent-
ly, the GM-CSF-induced myelomonocytic differentiation
of HSPC. Of note, we observed that RKIP exerts its role
in myelomonocytic lineage commitment of HSPC by act-
ing as an amplifier of GM-CSF signaling rather than
inducing the differentiation process on its own. This has
previously been shown for other alterations affecting
RAS-signaling as well43-45 and further highlights the impor-
tance of physiological and pathological GM-CSF/RAS-sig-
naling regulation in hematopoiesis. 
Increased myelomonocytic lineage commitment has
also been proposed to be an essential pre-phase of
myeloid neoplasms.46 Indeed, a role of RKIP in myeloid
leukemogenesis has been suggested previously, as its
somatic loss of expression was described as a frequent
event in AML.12,20-22 In line with our functional data pre-
sented above, it thereby correlated with myelomonocytic
AML phenotypes.12 In the current study, we further
strengthen these data by demonstrating that RKIP loss is
indeed of functional relevance for the development of
myelomonocytic leukemias. Again, it acted as an amplifi-
er of pathologic RAS-signaling, as it aggravated the activ-
ity of the RAS-MAPK/ERK pathway as well as the devel-
opment of a myelomonocytic MPD in mice that carry a
somatically inducible mutation in Nras within the
hematopoietic system. These data are further strength-
ened by our analysis of 41 primary CMML patients' spec-
imens, where we observed that  RKIP loss occurs in
almost 30% of cases on the one hand, and that it co-
occurs with RAS-signaling mutations on the other. The
data are, therefore, in agreement with previous studies of
our group, where we did observe a clinical correlation
and a functional synergism between RAS-signaling muta-
tions and RKIP loss in different subtypes of AML.12,20,22
They are also in agreement with previous observations,
where RAS-driven leukemogenesis could be significantly
aggravated by additional inactivation of RAS-MAPK/ERK
signaling inhibitors belonging to the dual specificity phos-
phatase (DUSP) and SPROUTY (Spry) families.15,39,41
Together with the previously shown aggravation of 
RAS-induced myeloid leukemogenesis by mutations in
ASXL1 and TET2,15,40 respectively, these data indicate that
activated RAS-signaling in human leukemias is far more
complex than initially believed and cannot be explained
by the occurrence of RAS-signaling mutations alone.
Finally, our data might also be of relevance for the
future development of targeted treatment approaches in
myeloid neoplasias, particularly for those aiming to
inhibit specific signal transduction cascades. This is based
on our observation that both the signaling and leuke-
mogenic effects of RAS mutations can be influenced by
aberrant expression of RAS-signaling regulator proteins.
So far, development of these agents has often been hin-
dered by the fact they showed disappointing efficacy in
clinical trials, even though the results from pre-clinical
models had been promising. An example for such a histo-
ry of drug development are MEK-inhibitors, which effi-
ciently attenuate Ras-driven MPD in mice, but show dis-
appointing results in clinical trials of myeloid malignan-
cies.47 Among others, one reason for this is the fact that
the monogenic pre-clinical model does not adequately
reflect the situation in myeloid neoplasia patients, who
usually exhibit a complex network of co-occurring and
interacting genetic aberrations within their neoplastic
clone. Therefore, more detailed knowledge of the co-
occurrence of mutational and non-mutational aberrations
in patients' specimens, as well as the functional conse-
quences thereof, might not only help to extend our
knowledge about the pathogenesis of this aggressive
malignancy, but also to more specifically select patients
that might profit from targeted therapies directed at cellu-
lar signaling. One successful example of this approach is
the recent observation that sensitivity to MEK inhibitors
in Nras-mutated mice can be increased by the co-occur-
rence of Tet2 deletion and decreased Spry2 expression lev-
els.15 With these data, the authors identified a specific sub-
group of RAS-mutated patients that will be the best candi-
dates for MEK-directed therapy. The fact that simultane-
ous occurrence of RASmutations and RKIP loss potentiat-
ed RAS-MAPK/ERK signaling as well, might identify
another group of patients with particular sensitivity to this
therapeutic approach. Future studies will, therefore, be
warranted to specifically test this hypothesis.
In conclusion, we show that the RAS-signaling regula-
tor RKIP plays a central role in myelomonocytic lineage
commitment of HSPC. We further show its relevance for
myelomonocytic leukemogenesis by demonstrating that
Rkip deletion enhances RAS-MAPK/ERK signaling and
aggravates the development of a myelomonocytic MPD
in Nras-mutated mice. Finally, we prove the clinical rele-
vance of these findings by showing that RKIP loss is a fre-
quent event in primary CMML patients' samples and fre-
quently co-occurs with RAS-signaling mutations. These
data establish RKIP as a novel player in RAS-driven
myeloid leukemogenesis.
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